Sutura is a pioneer in developing precision gene medicines for all human health.

Excellence through innovation
Sutura Therapeutics have developed a range of platform technologies designed to radically enhance the delivery and efficacy of RNA-targeting ‘Antisense Oligonucleotide’ based gene medicines. Their developmental pipeline seeks to address the current clinical translational bottlenecks, namely inefficient systemic cargo delivery and profound toxic side effects. Thus, they will develop high value gene-specific medicines that can either turn up OR turn down targeted genes that can improve the quality of life with rare, metabolic or age-related diseases.